Leading the Way in Life Science Technologies

GEN Exclusives

More »

BioMarket Trends

More »

For full access to this article login to GEN Select now.

Jan 15, 2014 (Vol. 34, No. 2)

Setting Sights on Ocular Disorders

New Therapeutic Options Are in Development for Age-Related Macular Degeneration

  • Age-related macular degeneration (AMD) is one of the leading causes of blindness. There are two forms of AMD—wet and dry. Currently, the majority of ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »